Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453732 | 0.93 | CYP1A2 (0.38) | CYP1A2HSD17B1HSD17B2ALDH1A1CYP2A6 | |
| SCHEMBL1453032 | 0.82 | CYP1A2 (0.37) | CYP1A2HSD17B1HSD17B2ALDH1A1CYP2A6 | |
| SCHEMBL1451928 | 0.74 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL1452331 | 0.69 | MEN1 (0.31) | — | |
| SCHEMBL1451774 | 0.69 | PBRM1 (0.32) | ALDH1A1 | |
| SCHEMBL1453542 | 0.68 | — | — | |
| SCHEMBL2968608 | 0.67 | KDM1A (0.33) | ALDH1A1 | |
| SCHEMBL1453390 | 0.66 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL1452775 | 0.65 | — | — | |
| SCHEMBL1452836 | 0.65 | CA12 (0.33) | ALDH1A1CYP2A6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1971621-A1 | PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007070045-A1 | PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | CYP1A2 1643/4885HSD17B1 3200/4885HSD17B2 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.